Biodesix® Named Innovative Company of the Year at 2016 IQ Awards
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
254 Results
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Biodesix will present data from three studies at SITC's annual meeting.
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
Clin-TOF successfully integrated into VeriStrat® workflow
Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.
Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells